Abstract
The heart is the first organ to form in the embryo, and all subsequent events in the life of the organism depend on its function. Inherited mutations in cardiac regulatory genes give rise to congenital heart disease, the most common form of human birth defects, and abnormalities of the adult heart represent the most prevalent cause of morbidity and mortality in the industrialized world. The past decade has marked a transition from physiological and functional studies of the heart toward a deeper understanding of cardiac function (and dysfunction) at genetic and molecular levels. These discoveries have provided new therapeutic approaches for prevention and palliation of cardiac disease and have raised new questions, challenges and opportunities for the future.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
American Heart Association. Heart Disease and Stroke Statistics: 2004 Update (American Heart Association, Dallas, Texas, USA, 2003).
Hoffman, J.I. Incidence of congenital heart disease: II. Prenatal incidence. Pediatr. Cardiol. 16, 155–165 (1995).
Schneider, V.A. & Mercola, M. Wnt antagonism initiates cardiogenesis in Xenopus laevis. Genes Dev. 15, 304–315 (2001).
Schultheiss, T.M., Burch, J.B. & Lassar, A.B. A role for bone morphogenetic proteins in the induction of cardiac myogenesis. Genes Dev. 11, 451–462 (1997).
Pandur, P., Lasche, M., Eisenberg, L.M. & Kuhl, M. Wnt-11 activation of a non-canonical Wnt signalling pathway is required for cardiogenesis. Nature 418, 636–641 (2002).
Marvin, M.J., Di Rocco, G., Gardiner, A., Bush, S.M. & Lassar, A.B. Inhibition of Wnt activity induces heart formation from posterior mesoderm. Genes Dev. 15, 316–327 (2001).
Bodmer, R. The gene tinman is required for specification of the heart and visceral muscles in Drosophila. Development 118, 719–729 (1993).
Azpiazu, N. & Frasch, M. tinman and bagpipe: two homeo box genes that determine cell fates in the dorsal mesoderm of Drosophila. Genes Dev. 7, 1325–1340 (1993).
Lints, T.J., Parsons, L.M., Hartley, L., Lyons, I. & Harvey, R.P. Nkx-2.5: a novel murine homeobox gene expressed in early heart progenitor cells and their myogenic descendants. Development 119, 419–431 (1993).
Komuro, I. & Izumo, S. Csx: a murine homeobox-containing gene specifically expressed in the developing heart. Proc. Natl. Acad. Sci. USA 90, 8145–8149 (1993).
Lyons, I. et al. Myogenic and morphogenetic defects in the heart tubes of murine embryos lacking the homeo box gene Nkx2-5. Genes Dev. 9, 1654–1666 (1995).
McKinsey, T.A., Zhang, C.L. & Olson, E.N. MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem. Sci. 27, 40–47 (2002).
Morin, S., Charron, F., Robitaille, L. & Nemer, M. GATA-dependent recruitment of MEF2 proteins to target promoters. EMBO J. 19, 2046–2055 (2000).
Belaguli, N.S. et al. Cardiac tissue enriched factors serum response factor and GATA-4 are mutual coregulators. Mol. Cell. Biol. 20, 7550–7558 (2000).
Wang, D. et al. Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor. Cell 105, 851–862 (2001).
Bao, Z.Z., Bruneau, B.G., Seidman, J.G., Seidman, C.E. & Cepko, C.L. Regulation of chamber-specific gene expression in the developing heart by Irx4. Science 283, 1161–1164 (1999).
Kelly, R.G., Zammit, P.S. & Buckingham, M.E. Cardiosensor mice and transcriptional subdomains of the vertebrate heart. Trends Cardiovasc. Med. 9, 3–10 (1999).
Kelly, R.G. & Buckingham, M.E. The anterior heart-forming field: voyage to the arterial pole of the heart. Trends Genet. 18, 210–216 (2002).
Kramer, K.L. & Yost, H.J. Cardiac left-right development: are the early steps conserved? Cold Spring Harb. Symp. Quant. Biol. 67, 37–43 (2002).
Srivastava, D., Cserjesi, P. & Olson, E.N. A subclass of bHLH proteins required for cardiac morphogenesis. Science 270, 1995–1999 (1995).
Yamagishi, H. et al. The combinatorial activities of Nkx2.5 and dHAND are essential for cardiac ventricle formation. Dev. Biol. 239, 190–203 (2001).
Cai, C.L. et al. Isl1 identifies a cardiac progenitor population that proliferates prior to differentiation and contributes a majority of cells to the heart. Dev. Cell 5, 877–889 (2003).
Fishman, M.C. & Olson, E.N. Parsing the heart: genetic modules for organ assembly. Cell 91, 153–156 (1997).
Garratt, A.N., Ozcelik, C. & Birchmeier, C. ErbB2 pathways in heart and neural diseases. Trends Cardiovasc. Med. 13, 80–86 (2003).
Chien, K.R. Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity. Semin. Oncol. 27, 9–14; discussion 92–100 (2000).
Stuckmann, I., Evans, S. & Lassar, A.B. Erythropoietin and retinoic acid, secreted from the epicardium, are required for cardiac myocyte proliferation. Dev. Biol. 255, 334–349 (2003).
Gitler, A.D., Lu, M.M., Jiang, Y.Q., Epstein, J.A. & Gruber, P.J. Molecular markers of cardiac endocardial cushion development. Dev. Dyn. 228, 643–650 (2003).
Gaussin, V. et al. Endocardial cushion and myocardial defects after cardiac myocyte-specific conditional deletion of the bone morphogenetic protein receptor ALK3. Proc. Natl. Acad. Sci. USA 99, 2878–2883 (2002).
Kim, R.Y., Robertson, E.J. & Solloway, M.J. Bmp6 and Bmp7 are required for cushion formation and septation in the developing mouse heart. Dev. Biol. 235, 449–466 (2001).
Farrell, M., Waldo, K., Li, Y.X. & Kirby, M.L. A novel role for cardiac neural crest in heart development. Trends Cardiovasc. Med. 9, 214–220 (1999).
Epstein, J.A. & Buck, C.A. Transcriptional regulation of cardiac development: implications for congenital heart disease and DiGeorge syndrome. Pediatr. Res. 48, 717–724 (2000).
Gourdie, R.G., Wei, Y., Kim, D., Klatt, S.C. & Mikawa, T. Endothelin-induced conversion of embryonic heart muscle cells into impulse-conducting Purkinje fibers. Proc. Natl. Acad. Sci. USA 95, 6815–6818 (1998).
Rentschler, S. et al. Neuregulin-1 promotes formation of the murine cardiac conduction system. Proc. Natl. Acad. Sci. USA 99, 10464–10469 (2002).
Rentschler, S. et al. Visualization and functional characterization of the developing murine cardiac conduction system. Development 128, 1785–1792 (2001).
Srivastava, D. & Olson, E.N. A genetic blueprint for cardiac development. Nature 407, 221–226 (2000).
Schott, J.J. et al. Congenital heart disease caused by mutations in the transcription factor NKX2-5. Science 281, 108–111 (1998).
Basson, C.T. et al. Mutations in human TBX5 [corrected] cause limb and cardiac malformation in Holt-Oram syndrome. Nat. Genet. 15, 30–35 (1997).
Garg, V. et al. GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature 424, 443–447 (2003).
Olson, E.N. & Schneider, M.D. Sizing up the heart: development redux in disease. Genes Dev. 17, 1937–1956 (2003).
Lowes, B.D. et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N. Engl. J. Med. 346, 1357–1365 (2002).
Antos, C.L. et al. Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. USA 99, 907–912 (2002).
Rothermel, B.A. et al. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. USA 98, 3328–3333 (2001).
Koch, W.J. et al. Cardiac function in mice overexpressing the β-adrenergic receptor kinase or a β-ARK inhibitor. Science 268, 1350–1353 (1995).
MacLellan, W.R. & Schneider, M.D. Death by design. Programmed cell death in cardiovascular biology and disease. Circ. Res. 81, 137–144 (1997).
Chien, K.R. Genomic circuits and the integrative biology of cardiac diseases. Nature 407, 227–232 (2000).
Hirota, H. et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 97, 189–198 (1999).
Dorn, G.W., II & Brown, J.H. Gq signaling in cardiac adaptation and maladaptation. Trends Cardiovasc. Med. 9, 26–34 (1999).
Molkentin, J.D. et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93, 215–228 (1998).
Frey, N., McKinsey, T.A. & Olson, E.N. Decoding calcium signals involved in cardiac growth and function. Nat. Med. 6, 1221–1227 (2000).
Sugden, P.H. Signalling pathways in cardiac myocyte hypertrophy. Ann. Med. 33, 611–622 (2001).
Molkentin, J.D. & Dorn, I.G., II. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu. Rev. Physiol. 63, 391–426 (2001).
Sano, M. et al. Activation and function of cyclin T–Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy. Nat. Med. 8, 1310–1317 (2002).
Zhang, C.L. et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110, 479–488 (2002).
McFarlane, S.I., Winer, N. & Sowers, J.R. Role of the natriuretic peptide system in cardiorenal protection. Arch. Intern. Med. 163, 2696–2704 (2003).
Konstam, M.A. Improving clinical outcomes with drug treatment in heart failure: what have trials taught? Am. J. Cardiol. 91, 9D–14D (2003).
Rockman, H.A., Koch, W.J. & Lefkowitz, R.J. Seven-transmembrane-spanning receptors and heart function. Nature 415, 206–212 (2002).
Packer, M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J. Am. Coll. Cardiol. 20, 248–254 (1992).
Dorn, G.W., II. Adrenergic pathways and left ventricular remodeling. J. Card. Fail. 8, S370–S373 (2002).
Bristow, M. Antiadrenergic therapy of chronic heart failure: surprises and new opportunities. Circulation 107, 1100–1102 (2003).
Bers, D.M. Cardiac excitation-contraction coupling. Nature 415, 198–205 (2002).
Schmidt, A.G., Edes, I. & Kranias, E.G. Phospholamban: a promising therapeutic target in heart failure? Cardiovasc. Drugs Ther. 15, 387–396 (2001).
Marx, S.O. et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101, 365–376 (2000).
Wehrens, X.H. et al. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell 113, 829–840 (2003).
Minamisawa, S. et al. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 99, 313–322 (1999).
Miyamoto, M.I. et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc. Natl. Acad. Sci. USA 97, 793–798 (2000).
Song, Q. et al. Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. J. Clin. Invest. 111, 859–867 (2003).
Haghighi, K. et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J. Clin. Invest. 111, 869–876 (2003).
Schmitt, J.P. et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299, 1410–1413 (2003).
Bolli, R. & Marban, E. Molecular and cellular mechanisms of myocardial stunning. Physiol. Rev. 79, 609–634 (1999).
Hoshijima, M., Pashmforoush, M., Knoll, R. & Chien, K.R. The MLP family of cytoskeletal Z disc proteins and dilated cardiomyopathy: a stress pathway model for heart failure progression. Cold Spring Harb. Symp. Quant. Biol. 67, 399–408 (2002).
Seidman, J.G. & Seidman, C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 104, 557–567 (2001).
Maass, A., Konhilas, J.P., Stauffer, B.L. & Leinwand, L.A. From sarcomeric mutations to heart disease: understanding familial hypertrophic cardiomyopathy. Cold Spring Harb. Symp. Quant. Biol. 67, 409–415 (2002).
Maron, B.J. Hypertrophic cardiomyopathy. Lancet 350, 127–133 (1997).
Dalloz, F., Osinska, H. & Robbins, J. Manipulating the contractile apparatus: genetically defined animal models of cardiovascular disease. J. Mol. Cell. Cardio. 33, 9–25 (2001).
Olson, T.M., Michels, V.V., Thibodeau, S.N., Tai, Y.S. & Keating, M.T. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 280, 750–752 (1998).
Towbin, J.A. & Bowles, N.E. The failing heart. Nature 415, 227–233 (2002).
Li, D. et al. Desmin mutation responsible for idiopathic dilated cardiomyopathy. Circulation 100, 461–464 (1999).
Fatkin, D. et al. An abnormal Ca2+ response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J. Clin. Invest. 106, 1351–1359 (2000).
Leinwand, L.A. Sex is a potent modifier of the cardiovascular system. J. Clin. Invest. 112, 302–307 (2003).
Keating, M.T. & Sanguinetti, M.C. Molecular and cellular mechanisms of cardiac arrhythmias. Cell 104, 569–580 (2001).
Marban, E. Cardiac channelopathies. Nature 415, 213–218 (2002).
Wang, Q. et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 80, 805–811 (1995).
Sanguinetti, M.C., Jiang, C., Curran, M.E. & Keating, M.T. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81, 299–307 (1995).
Splawski, I., Tristani-Firouzi, M., Lehmann, M.H., Sanguinetti, M.C. & Keating, M.T. Mutations in the hminK gene cause long QT syndrome and suppress IKs function. Nat. Genet. 17, 338–340 (1997).
Kirchhoff, S. et al. Abnormal cardiac conduction and morphogenesis in connexin40 and connexin43 double-deficient mice. Circ. Res. 87, 399–405 (2000).
Kasahara, H. et al. Progressive atrioventricular conduction defects and heart failure in mice expressing a mutant Csx/Nkx2.5 homeoprotein. J. Clin. Invest. 108, 189–201 (2001).
Bruneau, B.G. et al. A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease. Cell 106, 709–721 (2001).
Nguyen-Tran, V.T. et al. A novel genetic pathway for sudden cardiac death via defects in the transition between ventricular and conduction system cell lineages. Cell 102, 671–682 (2000).
Orlic, D. et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc. Natl. Acad. Sci. USA 98, 10344–10349 (2001).
Lanza, R. et al. Regeneration of the infected heart with stem cell derived by nuclear transplantation. Circ. Res. 94, 820–827 (2004)
Murry, C.E., Whitney, M.L., Laflamme, M.A., Reinecke, H. & Field, L.J. Cellular therapies for myocardial infarct repair. Cold Spring Harb. Symp. Quant. Biol. 67, 519–526 (2002).
Pasumarthi, K.B. & Field, L.J. Cardiomyocyte cell cycle regulation. Circ. Res. 90, 1044–1054 (2002).
Murry, C.E. et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 428, 664–668 (2004).
Balsam, L.B. et al. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 428, 668–675 (2004).
Chien, K.R. Stem cells: lost in translation. Nature 428, 607–608 (2004).
Nygren, J.M. et al. Bone marrow–derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat. Med. 10, 494–501 (2004).
Assmus, B. et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 106, 3009–3017 (2002).
Reinecke, H., Poppa, V. & Murry, C.E. Skeletal muscle stem cells do not transdifferentiate into cardiomyocytes after cardiac grafting. J. Mol. Cell. Cardiol. 34, 241–249 (2002).
Beltrami, A.P. et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114, 763–776 (2003).
Oh, H. et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc. Natl. Acad. Sci. USA 100, 12313–12318 (2003).
Wu, X., Ding, S., Ding, Q., Gray, N.S. & Schultz, P.G. Small molecules that induce cardiomyogenesis in embryonic stem cells. J. Am. Chem. Soc. 126, 1590–1591 (2004).
Poss, K.D., Wilson, L.G. & Keating, M.T. Heart regeneration in zebrafish. Science 298, 2188–2190 (2002).
Leferovich, J.M. et al. Heart regeneration in adult MRL mice. Proc. Natl. Acad. Sci. USA 98, 9830–9835 (2001).
Bush, E. et al. A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway. Proc. Natl. Acad. Sci. USA 101, 2870–2875 (2004).
Acknowledgements
I am grateful to past and present members of my lab for insightful comments and scientific contributions.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Olson, E. A decade of discoveries in cardiac biology. Nat Med 10, 467–474 (2004). https://doi.org/10.1038/nm0504-467
Issue Date:
DOI: https://doi.org/10.1038/nm0504-467
This article is cited by
-
Fibroblast transition to an endothelial “trans” state improves cell reprogramming efficiency
Scientific Reports (2021)
-
Effects of Estrogen on Cardiac mRNA and LncRNA Expression Profiles in Hypertensive Mice
Journal of Cardiovascular Translational Research (2021)
-
The Effects of Neuropeptide Y Overexpression on the Mouse Model of Doxorubicin-Induced Cardiotoxicity
Cardiovascular Toxicology (2020)
-
Shenfu Injection attenuates rat myocardial hypertrophy by up-regulating miR-19a-3p expression
Scientific Reports (2018)
-
BRG1-SWI/SNF-dependent regulation of the Wt1 transcriptional landscape mediates epicardial activity during heart development and disease
Nature Communications (2017)